Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mast cell dipeptidyl peptidase I mediates survival from sepsis
Jon Mallen–St. Clair, Christine T.N. Pham, S. Armando Villalta, George H. Caughey, Paul J. Wolters
Jon Mallen–St. Clair, Christine T.N. Pham, S. Armando Villalta, George H. Caughey, Paul J. Wolters
View: Text | PDF
Article Immunology

Mast cell dipeptidyl peptidase I mediates survival from sepsis

  • Text
  • PDF
Abstract

Sepsis is a common, life-threatening disease for which there is little treatment. The cysteine protease dipeptidyl peptidase I (DPPI) activates granule-associated serine proteases, several of which play important roles in host responses to bacterial infection. To examine DPPI’s role in sepsis, we compared DPPI–/– and DPPI+/+ mice using the cecal ligation and puncture (CLP) model of septic peritonitis, finding that DPPI–/– mice are far more likely to survive sepsis. Outcomes of CLP in mice lacking mast cell DPPI reveal that the absence of DPPI in mast cells, rather than in other cell types, is responsible for the survival advantage. Among several cytokines surveyed in peritoneal fluid and serum, IL-6 is highly and differentially expressed in DPPI–/– mice compared with DPPI+/+ mice. Remarkably, deleting IL-6 expression in DPPI–/– mice eliminates the survival advantage. The increase in IL-6 in septic DPPI–/– mice, which appears to protect these mice from death, may be related to reduced DPPI-mediated activation of mast cell tryptase and other peptidases, which we show cleave IL-6 in vitro. These results indicate that mast cell DPPI harms the septic host and that DPPI is a novel potential therapeutic target for treatment of sepsis.

Authors

Jon Mallen–St. Clair, Christine T.N. Pham, S. Armando Villalta, George H. Caughey, Paul J. Wolters

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Selective absence of mast cell DPPI improves survival from sepsis. (a) S...
Selective absence of mast cell DPPI improves survival from sepsis. (a) Survival of mast cell–deficient KitWsh/KitWsh mice selectively reconstituted with DPPI–/– BMMCs (PMC-DPPI–/– mice, n = 40) were compared with KitWsh/KitWsh mice selectively reconstituted with DPPI+/+ BMMCs (PMC-DPPI+/+ mice, n = 65), and with KitWsh/KitWsh (n = 20) mice for 8 days following CLP. Note that survival of mice lacking DPPI solely in mast cells (PMC-DPPI–/– mice) is significantly better than that of PMC-DPPI+/+ mice. *P = 0.026 for PMC-DPPI–/– vs. PMC-DPPI+/+ mice. **P = 0.22 for KitWsh/KitWsh vs. PMC-DPPI+/+ mice. (b) IL-6 levels are higher in the peritoneal lavage of PMC-DPPI–/– mice. Concentrations of IL-6 were measured by ELISA in lavage fluid obtained from PMC-DPPI+/+ and PMC-DPPI–/– mice 2 hours after CLP. *P = 0.05 for PMC-DPPI–/– mice vs. PMC-DPPI+/+ mice. (c) Mast cell proteases cleave IL-6. IL-6 was incubated alone (lane 1) or with mMCP-4 (lane 2), DPPI (lane 3), or mMCP-6 (lane 4) for 3 hours at 37°C. Note the appearance of a new 23-kDa band in the mMCP-6–treated sample (black arrow), and new, faint bands in the DPPI-treated sample (arrowheads).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts